


DATA MENGENAI PATEN ARV TERKAIT PRODUKSI TENOVOFIR

Sumber : <http://www.drugpatentwatch.com/ultimate/preview/ingredient/index.php?query=lopinavir%3B+ritonavir>

Summary for Tradename: TRUVADA

Patents: 10
Applicants: 1
NDAs: 1
2008 Sales: \$775,787,000
Therapeutic Class: [Antivirals](#)



Latest news for TRUVADA

[U.S. expands HIV/AIDS programs in Caribbean](#)

13 May 2010, 2:32 am

[Press Release](#)

11 May 2010, 9:48 am

[Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI](#)

29 April 2010, 5:56 am

[Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada® and Tibotec ...](#)

27 April 2010, 8:30 am

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Exclusivity Expiration
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	021752	Aug 2, 2004	RX	Yes	5,210,085*PED			Y	Nov 11, 2010	
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	021752	Aug 2, 2004	RX	Yes	5,814,639*PED			Y	Mar 29, 2016	
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	021752	Aug 2, 2004	RX	Yes	5,914,331*PED		Y	Y	Jan 2, 2018	

Info Paten: 5,210,085*PED

Summary for Patent: 5,210,085

Title: Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds

Abstract: The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularly in the prevention and treatment of AIDS; and the compounds themselves. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds and related compounds.

Inventor(s): Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)

Assignee: Emory University (Atlanta, GA)

Application Number: 07/659,760

Patent Claim Types: *Use; Composition;*

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Patex_Term
Gilead	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	021937	Jul 12, 2006	RX	Yes	5,210,085*PED			Y	Nov 11, 2010	
Gilead	EMTRIVA	emtricitabine	021500	Jul 2, 2003	RX	Yes	5,210,085*PED			Y	Nov 11, 2010	
Gilead	EMTRIVA	emtricitabine	021896	Sep 28, 2005	RX	Yes	5,210,085*PED			Y	Nov 11, 2010	

Info Paten: 5,814,639*PED

Summary for Patent: 5,814,639

Title: Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds

Abstract: The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularly in the

prevention and treatment of AIDS; and the compounds themselves. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds and related compounds.

Inventor(s): Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)

Assignee: Emory University (Atlanta, GA)

Application Number: 08/017,820

Patent Claim Types: Use; Composition;

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Patex_Term
Gilead	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	021937	Jul 12, 2006	RX	Yes	5,814,639*PED			Y	Mar 29, 2016	
Gilead	EMTRIVA	emtricitabine	021500	Jul 2, 2003	RX	Yes	5,814,639*PED			Y	Mar 29, 2016	
Gilead	EMTRIVA	emtricitabine	021896	Sep 28, 2005	RX	Yes	5,814,639*PED			Y	Mar 29, 2016	

Summary for NDA: 021937

Tradename:	ATRIPLA
Applicant:	Gilead
Ingredient:	efavirenz; emtricitabine; tenofovir disoproxil fumarate
Patents:	15

Summary for product number 001:

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET; ORAL	Strength	600MG;200MG;300MG
Approval Date:	Jul 12, 2006	TE:		RLD:	Yes
Patent:	5,210,085*PED	Patent Expiration:	Nov 11, 2010	Product Flag?	
Patented Use:				Substance Flag?	
				Delist Request?	Y